Noticias de CAPR_US | Rava Bursátil

31/08/2026 CAPR_US — The Globe and Mail

Capricor Therapeutics, Inc. (CAPR) Securities Fraud Class Action Lawsuit Filed; September 28, 2026, Lead Plaintiff Deadline

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

31/08/2026 CAPR_US — GlobeNewswire

Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ:

31/08/2026 CAPR_US — scanx.trade

Capricor shares rise 22% as Lancet publishes Deramiocel trial data

Capricor Therapeutics stock recovered significantly following the publication of its Phase 3 HOPE-3 trial results in The Lancet, which confirmed Deramiocel

31/08/2026 CAPR_US — GlobeNewswire

Lead Plaintiff Deadlines in Shareholder Class Action

31/08/2026 CAPR_US — The National Law Review

CAPR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Capricor I

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options

30/08/2026 CAPR_US — ACCESS Newswire

CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

30/08/2026 CAPR_US — GlobeNewswire

Kessler Topaz Meltzer & Check, LLP - INVESTOR DEADLINE

30/08/2026 CAPR_US — scanx.trade

Piper Sandler Downgrades Capricor Therapeutics, Cuts Target to $2

Piper Sandler analyst Edward Tenthoff downgraded Capricor Therapeutics (CAPR) from Overweight to Neutral. The firm lowered its price target from $58 to $2, indicating a severe devaluation expectation for the stock.

30/08/2026 CAPR_US — nny360.com

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Nationally Recognized Firm Urges Capricor Investors to Explore Class Action Representation

29/08/2026 CAPR_US — GlobeNewswire

ROSEN, A LONGSTANDING FIRM, Encourages Capricor

29/08/2026 CAPR_US — GlobeNewswire

ROSEN, A LONGSTANDING FIRM, Encourages Capricor

29/08/2026 CAPR_US — The Globe and Mail

Capricor Therapeutics, Inc. (CAPR) Action Lawsuit: Investors Face September 28, 2026, Deadline

29/08/2026 CAPR_US — ACCESS Newswire

CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

28/08/2026 CAPR_US — PR Newswire

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

/PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor...

28/08/2026 CAPR_US — The Globe and Mail ES ← EN

Kaplan Fox anima a los inversores de Capricor Therapeutics, Inc. (NASDAQ: CAPR) a ponerse en contacto con la empresa antes de la fecha límite del 28 de septiembre de 2026

Información detallada de precios de Bank of America Corp (BAC-N) de The Globe and Mail, incluidos gráficos y operaciones.

28/08/2026 CAPR_US — Barchart.com

Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026

28/08/2026 CAPR_US — Barchart.com

Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026

28/08/2026 CAPR_US — news.alphastreet.com

A Rejected Vote Pushes Capricor (CAPR) Toward a Narrower Path

28/08/2026 CAPR_US — Barchart.com

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline